Reaction Details Report a problem with these data
Target
IgG receptor FcRn large subunit p51
Ligand
BDBM50270964
Substrate
n/a
Meas. Tech.
ChEMBL_552584 (CHEMBL956456)
IC50
2200±n/a nM
Citation
 Mezo, AR; McDonnell, KA; Castro, A; Fraley, C Structure-activity relationships of a peptide inhibitor of the human FcRn:human IgG interaction. Bioorg Med Chem 16:6394-405 (2008) [PubMed]  Article 
Target
Name:
IgG receptor FcRn large subunit p51
Synonyms:
FCGRN_HUMAN | FCGRT | FCRN
Type:
PROTEIN
Mol. Mass.:
39742.86
Organism:
Homo sapiens (Human)
Description:
ChEMBL_627631
Residue:
365
Sequence:
MGVPRPQPWALGLLLFLLPGSLGAESHLSLLYHLTAVSSPAPGTPAFWVSGWLGPQQYLSYNSLRGEAEPCGAWVWENQVSWYWEKETTDLRIKEKLFLEAFKALGGKGPYTLQGLLGCELGPDNTSVPTAKFALNGEEFMNFDLKQGTWGGDWPEALAISQRWQQQDKAANKELTFLLFSCPHRLREHLERGRGNLEWKEPPSMRLKARPSSPGFSVLTCSAFSFYPPELQLRFLRNGLAAGTGQGDFGPNSDGSFHASSSLTVKSGDEHHYCCIVQHAGLAQPLRVELESPAKSSVLVVGIVIGVLLLTAAAVGGALLWRRMRSGLPAPWISLRGDDTGVLLPTPGEAQDADLKDVNVIPATA
  
Inhibitor
Name:
BDBM50270964
Synonyms:
(2R)-2-{[(2S)-1-[(2S)-2-[(2S)-2-{[(3S,6R,8aR)-6-[(2S)-2-[(2S)-2-{2-[(2S,3R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-phenylpropanamido]-3-methyl-3-sulfanylbutanamido]-3-hydroxybutanamido]acetamido}-3-(1H-imidazol-5-yl)propanamido]-3-phenylpropanamido]-5-oxo-hexahydro-2H-pyrido[2,1-b][1,3]thiazol-3-yl]formamido}-4-methylpentanamido]-3-(4-hydroxyphenyl)propanoyl]pyrrolidin-2-yl]formamido}-3-sulfanylpropanoic acid | CHEMBL525583
Type:
Small organic molecule
Emp. Form.:
C72H100N18O16S3
Mol. Mass.:
1569.87
SMILES:
CC(C)C[C@H](NC(=O)[C@H]1CS[C@@H]2CC[C@@H](NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](Cc3cnc[nH]3)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@@H](N)CCCN=C(N)N)C(C)(C)S)[C@@H](C)O)C(=O)N12)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(O)=O |r,wU:4.4,11.84,62.65,18.26,wD:43.45,75.79,103.109,29.37,84.88,51.61,8.7,14.14,47.49,99.106,(26.5,-35.7,;25.43,-36.79,;25.84,-38.27,;23.94,-36.41,;22.86,-37.5,;21.39,-37.28,;20.89,-35.83,;19.38,-35.53,;21.9,-34.67,;23.43,-34.81,;24.04,-33.4,;22.88,-32.39,;22.86,-30.86,;21.53,-30.11,;20.21,-30.89,;18.87,-30.14,;17.51,-30.87,;17.52,-32.42,;16.22,-30,;16.22,-28.45,;17.56,-27.68,;18.88,-28.45,;20.22,-27.69,;20.22,-26.15,;18.88,-25.38,;17.55,-26.15,;15,-30.89,;13.64,-30.17,;13.65,-28.62,;12.37,-31.03,;12.37,-32.58,;13.71,-33.35,;15.17,-32.86,;16.08,-34.1,;15.19,-35.35,;13.72,-34.89,;10.98,-30.14,;9.62,-30.87,;9.63,-32.41,;8.34,-30,;7.13,-30.89,;5.77,-30.17,;5.78,-28.62,;4.5,-31.03,;3.28,-30.14,;1.95,-30.92,;1.96,-32.47,;.61,-30.15,;-.72,-30.94,;-2.09,-30.22,;-2.08,-28.67,;-3.37,-31.08,;-3.37,-32.64,;-2.03,-33.42,;-.69,-32.65,;.65,-33.42,;.65,-34.97,;-.69,-35.74,;-2.03,-34.97,;-4.58,-30.2,;-5.95,-30.92,;-5.94,-32.47,;-7.24,-30.05,;-8.46,-30.94,;-7.24,-28.49,;-5.9,-27.72,;-5.89,-26.17,;-4.56,-25.45,;-4.52,-23.9,;-3.17,-23.17,;-5.84,-23.1,;.59,-28.61,;-.95,-28.62,;.59,-27.06,;2.14,-28.6,;4.5,-32.58,;3.16,-33.35,;5.83,-33.35,;20.22,-32.43,;18.9,-33.22,;21.56,-33.17,;23.17,-39,;22.09,-40.1,;24.64,-39.44,;24.88,-40.92,;23.8,-42.02,;23.79,-43.55,;25.13,-44.32,;25.12,-45.86,;23.79,-46.63,;23.78,-48.17,;22.45,-45.85,;22.46,-44.31,;26.39,-41.19,;27.47,-40.1,;26.85,-42.66,;25.94,-43.89,;26.83,-45.15,;28.3,-44.69,;28.31,-43.15,;29.56,-42.25,;29.41,-40.72,;30.97,-42.89,;31.22,-44.36,;30.13,-45.47,;30.54,-46.94,;32.72,-44.65,;33.18,-46.12,;33.81,-43.56,)|
Structure:
Search PDB for entries with ligand similarity: